Page 2 - Multicenter Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MDS patients who have failed prior HMA therapy selected as first indication to advance into Phase 2 3 mg/kg and 6 mg/kg doses selected in accordance with FDA’s Project Optimus initiative guidancePhase 2 part of the study will recruit 32 HMA-failed MDS patients for 1:1 dose randomization with possible data release after 20 patients have received more than two treatment cycles Company announcement, Inside Information TURKU, Finland and BOSTON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceutical

– Three Oral Presentations and 30 Posters Across HBV, HCV, HDV, and Fibrosis, Including Late-Breaking Data on Hepcludex® in HDV, Demonstrate Gilead’s Commitment to Addressing Unmet Needs for...

– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal Study in Sickle Cell Disease, Compared to the Placebo Arm; Data Support

Sickle cell disease, a chronic debilitating disorder, is characterized by ongoing hemolytic anemia, vaso-occlusive events, and progressive organ damage.

– First-of-its-kind authorization provides potential marketing differentiation and opportunities for largest testing category – – Testament to Invitae's product and lab quality –  – Sets...